Drug Profile
Research programme: genetically modified tumour-infiltrating lymphocytes - PolyBioCept
Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator PolyBioCept
- Class Cell therapies; Gene therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Cancer in Sweden (Parenteral)
- 15 Sep 2016 Karolinska University Hospital plans two phase I trials for Glioblastoma and Pancreatic cancer in Sweden
- 15 Sep 2016 Iovance Biotherapeutics in-licenses tumour-infiltrating lymphocytes technology and patents from PolyBioCep